Bausch Health Companies Inc.BHC.TO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · bauschhealth.com

Bausch Health Companies Inc. is a global diversified healthcare company headquartered in Laval, Quebec, that develops, manufactures, and markets products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, and eye health. The company operates through its majority-owned subsidiary Bausch + Lomb Corporation and serves patients and healthcare providers worldwide with a team of over 7,000 employees.

Key ratios

Operating cash flow growth

19.5%TTM

2025 -12.3%2024 54.8%

FCF / Sales

13.2%TTM

2025 9.8%2024 13.1%2023 9.3%

Net margin

-10.1%TTM

2025 1.5%2024 -0.5%2023 -6.8%

ROA

6.6%TTM

2025 5.2%2024 4.4%2023 3.8%

ROE

436.4%TTM

2025 436.4%2023 -686.5%

Revenue growth

10.1%TTM

2025 6.7%2024 9.9%2023 7.8%

Recent news

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets 2026-09-08 · CNW (Pr)SILIQ (brodalumab injection) Now Reimbursed Under Alberta's Public Drug Plan, Improving Access for Eligible Patients with Moderate to Severe Plaque Psoriasis 2026-09-08 · CNW Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia 2026-09-01 · CNW Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board 2026-08-06 · CNW Bausch Health Announces Second Quarter 2026 Results, Raises Guidance 2026-07-29 · CNW ELIDEL (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan 2026-07-28 · CNW Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026 2026-07-07 · Newswire (CNW)Québec is the first province to list (Pr)OKEDI(MC) on the public drug reimbursement formulary for the treatment of schizophrenia 2026-07-06 · Newswire (CNW)Michael Goettler Resigns from Bausch Health's Board of Directors 2026-07-01 · PR Newswire Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of PrOKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia 2026-06-09 · Bausch Health IR

Track BHC.TO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer